LRMRHealthcareSmall-Cap
Larimar Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Larimar Therapeutics, Inc. (LRMR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are LRMR insiders buying or selling?
Larimar Therapeutics, Inc. insiders reported 19 open-market buys ($136.5M) and 1 sells ($320.0K) across 20 Form 4 filings — a net buying position of $136.2M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 8, 2026)
Total Form 4 filings
20
SEC EDGAR
Insider filers
9
Insider buys (19)
$136.5M
Insider sells (1)
$320.0K
Insider sentiment
Net buyingNet insider flow of $136.2M in net buying. 1 insider buy in the last 90 days.
Recent LRMR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Thomas Edward Hamilton | Director | Purchase | 50.0K | $3.34 | $166.9K |
| Mar 3, 2026 | James E Flynn | Director, 10% Owner | Purchase | 5.0M | $5.00 | $25.0M |
| Mar 2, 2026 | Thomas Edward Hamilton | Director | Purchase | 100.0K | $5.00 | $500.0K |
| Mar 2, 2026 | Frank E Thomas | Director | Purchase | 5.0K | $5.00 | $25.0K |
| Mar 2, 2026 | Jeffrey W Sherman | Director | Purchase | 5.0K | $5.00 | $25.0K |
| Aug 4, 2025 | Flynn James E | Director, 10% Owner | Purchase | 9.4M | $3.20 | $30.0M |
| May 31, 2024 | Thomas Edward Hamilton | Director | Purchase | 57.2K | $8.74 | $500.0K |
| Feb 16, 2024 | Flynn James E | Director, 10% Owner | Purchase | 4.3M | $8.74 | $37.5M |
| Feb 15, 2024 | Frank E Thomas | Director | Purchase | 2.0K | $11.00 | $22.0K |
| Dec 8, 2023 | Gopi Shankar | Chief Development Officer | Purchase | 5.0K | $3.73 | $18.7K |
| May 18, 2023 | Michael Celano | Chief Financial Officer | Purchase | 5.0K | $3.73 | $18.6K |
| May 18, 2023 | Carole Ben-Maimon | President and CEO | Purchase | 5.0K | $3.71 | $18.5K |
| May 18, 2023 | Joseph Truitt | Director | Purchase | 2.8K | $3.73 | $10.3K |
| Sep 21, 2022 | Flynn James E | Director, 10% Owner | Purchase | 11.1M | $3.15 | $35.0M |
| Sep 20, 2022 | Thomas Edward Hamilton | Director | Purchase | 317.5K | $3.15 | $1000.0K |
| Sep 19, 2022 | Michael Celano | Chief Financial Officer | Purchase | 31.7K | $3.15 | $100.0K |
| Sep 19, 2022 | Carole Ben-Maimon | President and CEO | Purchase | 31.7K | $3.15 | $100.0K |
| Jul 2, 2021 | Flynn James E | Director, 10% Owner | Purchase | 685.7K | $8.75 | $6.0M |
| Jul 2, 2021 | Thomas Edward Hamilton | Director | Purchase | 56.7K | $8.75 | $496.2K |
| Jun 29, 2018 | Thomas E. Hughes | President and Chief Scientific Officer | Sale | 32.0K | $10.00 | $320.0K |
Showing the 20 most recent of 20 Form 4 filings for Larimar Therapeutics, Inc..
Most active LRMR insiders
- Flynn James E5 filings
- Thomas Edward Hamilton5 filings
- Carole Ben-Maimon2 filings
- Frank E Thomas2 filings
- Michael Celano2 filings
Ask anything about LRMR insider activity
Use Trabud's AI agent to query Larimar Therapeutics, Inc.'s Form 4 history in plain English — "Show me LRMR CEO purchases this year" or compare it against any other ticker.
Open the AI agentLRMR insider trading FAQ
Are Larimar Therapeutics, Inc. insiders buying or selling?
Across 20 SEC Form 4 filings, Larimar Therapeutics, Inc. (LRMR) insiders reported 19 open-market purchases totaling $136.5M and 1 sales totaling $320.0K. That is a net buying position of $136.2M.
How many insiders trade LRMR stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Larimar Therapeutics, Inc.. The most recent filing was accepted on Jul 8, 2026.
Where does Trabud get LRMR insider trading data?
All LRMR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.